(Q35947797)

English

Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 August 2017

Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer (English)

1 reference

Europe PubMed Central

11 August 2017

Adaptive radiation therapy

0 references

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

2

object named as

Yair Lotan

1 reference

Europe PubMed Central

11 August 2017

author name string

Joseph C Hodges

1

1 reference

Europe PubMed Central

11 August 2017

Thomas P Boike

3

1 reference

Europe PubMed Central

11 August 2017

Rhonda Benton

4

1 reference

Europe PubMed Central

11 August 2017

Alyson Barrier

5

1 reference

Europe PubMed Central

11 August 2017

Robert D Timmerman

6

1 reference

Europe PubMed Central

11 August 2017

language of work or name

0 references

publication date

1 May 2012

1 reference

Europe PubMed Central

11 August 2017

Journal of Oncology Practice

1 reference

Europe PubMed Central

11 August 2017

8

1 reference

Europe PubMed Central

11 August 2017

3 Suppl

1 reference

Europe PubMed Central

11 August 2017

e31s-7s

1 reference

Europe PubMed Central

11 August 2017

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

2 October 2017

Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

2 October 2017

Cost implications of the rapid adoption of newer technologies for treating prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

2 October 2017

Projections of the cost of cancer care in the United States: 2010-2020.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

2 October 2017

Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

2 October 2017

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

2 October 2017

Stereotactic body radiation therapy for inoperable early stage lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

2 October 2017

Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

2 October 2017

Comparative effectiveness and health care spending--implications for reform

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

2 October 2017

Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

2 October 2017

Adenocarcinoma of the prostate: an expensive way to die.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

2 October 2017

High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

2 October 2017

Is alpha/beta for prostate tumors really low?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

2 October 2017

Cost-effectiveness of androgen suppression therapies in advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

2 October 2017

Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

2 October 2017

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

2 October 2017

A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

2 October 2017

Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

11 July 2018

Health-related quality of life among patients with metastatic prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

11 July 2018

Stereotactic body radiotherapy for prostate cancer: current results of a phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

24 September 2018

Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

24 September 2018

Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

24 September 2018

Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

24 September 2018

Is Proton Beam Therapy Cost Effective in the Treatment of Adenocarcinoma of the Prostate?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

24 September 2018

Second-line chemotherapy for prostate cancer: patient characteristics and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

24 September 2018

Utilities for prostate cancer health states in men aged 60 and older.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

24 September 2018

Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

24 September 2018

Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

24 September 2018

Is the alpha/beta ratio for prostate cancer low?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

24 September 2018

Markov models in medical decision making: a practical guide.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3348607

24 September 2018

Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22942832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22942832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/22942832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fractionation and protraction for radiotherapy of prostate carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22942832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/22942832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determining transition probabilities: confusion and suggestions

1 reference

https://pubmed.ncbi.nlm.nih.gov/22942832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JOP.2012.000548

1 reference

Europe PubMed Central

11 August 2017

release_zpzr3rndfnd6pgbjuubvixkszu

1 reference

https://api.fatcat.wiki/v0/release/zpzr3rndfnd6pgbjuubvixkszu

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35947797&oldid=1856181980"